Delving into the Latest Updates on Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms

Cytotoxic T-cell therapy, Dendritic cell therapy, MASCT I

+ [6]

Target-

Mechanism

Cytotoxic T lymphocytes stimulants, Immunologic cytotoxicity, Immunostimulants

Therapeutic Areas

NeoplasmsNervous System DiseasesSkin and Musculoskeletal Diseases+ [3]

Active Indication

Desmoplastic Small Round Cell TumorEndometrial Stromal SarcomaHemangiosarcoma+ [10]

Inactive Indication

Advanced gastric carcinomaAdvanced Malignant Solid Neoplasmmetastatic non-small cell lung cancer+ [3]

Originator Organization

HRYZ (Shanghai) Biotech Co., Ltd.

Active Organization

HRYZ (Shanghai) Biotech Co., Ltd.

Inactive Organization

The First People's Hospital of Lianyungang

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估接受标准一线化疗结束后临床获益的尿路上皮癌受试者使用MASCT-I+BSC 维持治疗较单采PBMC 细胞+BSC 对PFS 的改善情况；次要目的：评估MASCT-I+BSC 用于标准一线化疗结束后维持治疗的其他疗效指标，并进一步评估MASCT-I 用于这一人群的安全性。

[Translation]

The primary objective is to evaluate the improvement in PFS of MASCT-I+BSC maintenance therapy compared with single-collected PBMC cells+BSC in subjects with urothelial carcinoma who have achieved clinical benefits after standard first-line chemotherapy. The secondary objective is to evaluate other efficacy indicators of MASCT-I+BSC for maintenance therapy after standard first-line chemotherapy, and further evaluate the safety of MASCT-I in this population.

Start Date09 Jan 2023

Sponsor / Collaborator

Hengruiyuanzheng (Shenzhen) Biotechnology Co., Ltd.

[+1]

CTR20190852 / CompletedPhase 1

单中心，I期临床研究，评价多抗原自体免疫细胞注射液（MASCT-I）对晚期实体瘤患者的安全性和耐受性

[Translation] A single-center, phase I clinical study evaluating the safety and tolerability of multi-antigen autologous immune cell injection (MASCT-I) in patients with advanced solid tumors

主要目的: MASCT-I对晚期转移或复发且各种标准治疗失败的实体瘤患者的安全性和耐受性。次要目的：MASCT-I给药后的免疫响应。探索性目的: 初步探索MASCT-I的疗效。

[Translation]

Primary objective: To investigate the safety and tolerability of MASCT-I in patients with solid tumors that have advanced metastatic or recurrent disease and have failed various standard treatments. Secondary objective: To investigate the immune response after administration of MASCT-I. Exploratory objective: To preliminarily explore the efficacy of MASCT-I.

Start Date21 Apr 2020

Sponsor / Collaborator

Hengruiyuanzheng (Shenzhen) Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.)

Login to view more data

100 Translational Medicine associated with Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.)

Login to view more data

6

Literatures (Medical) associated with Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.)

14 Mar 2024·Technology and Health Care

Effect of additional dead space using end-tidal CO2 measurement on ventilating preterm infants: An experimental study

Article

Author: Mur, Linda ; Annon-Eberharter, Natalee ; Wald, Martin ; Gombos, Petra

BACKGROUND: Dead space is the part of the airway where no gas exchange takes place. Any increase in dead space volume has a proportional effect on the required tidal volume and thus on the risk of ventilation-induced lung injury. Inserts that increase dead space are therefore not used in small preterm infants. This includes end-tidal CO2 measurement. OBJECTIVE: The aim of this study was to investigate the effect of the end-tidal CO2 measurement adapter on ventilation. METHODS: In an experimental setup, an end-tidal CO2 measurement adapter, three different pneumotachographs (PNT-A, PNT-B, PNT-Neo), and a closed suction adapter were combined in varying set-ups. The time required for CO2 elimination by a CO2-flooded preterm infant test lung was measured. RESULTS: PNT-A prolonged CO2 elimination time by 0.9 s (+3.3%), Neo-PNT by 3.2 s (+11.6%) and PNT-B by 9.0 s (+32.7%). The end-tidal CO2 measurement adapter prolonged the elimination time by an additional second without the pneumotachograph (+3.6%) and in combination with PNT-A (+3.1%) and PNT-Neo (+3.1%). In conjunction with PNT-B, the end-tidal CO2 measurement adapter reduced the elimination time by 0.3 seconds (-1%). The use of a closed suction adaptor increased the CO2 elimination time by a further second with PNT-Neo (+3.1%) and by an additional two seconds with no flow sensor (+6.9%), with PNT-A (+6.4%) and with PNT-B (+5.5%). CONCLUSION: The flow sensor had the greatest influence on ventilatory effort, while end-tidal CO2 measurement had only a moderate effect. The increased ventilatory effort levied by the CO2 measurement was dependent on the flow sensor selected. The use of closed suctioning more negatively impacted ventilatory effort than did end-tidal CO2 measurement.

01 Nov 2022·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Modulation of the lipophilicity and molecular size of thiosemicarbazone inhibitors to regulate tyrosinase activity

Article

Author: Zeng, Huajin ; Chen, Jingwen ; Cao, Shuhong ; Zhang, Qinfang ; Wang, Dandan ; Cheng, Run ; Shi, Wenyan

A group of 5-methylsalicylaldehyde thiosemicarbazone derivatives (HMTs) bearing different lipophilic and steric substituents attached at the 3-position of cresol ring were synthesized and investigated as mushroom tyrosinase (TYR) inhibitors. The ability of HMTs to inhibit the diphenolase activity of TYR was evaluated with L-DOPA as substrate by determining IC₅₀ values in relation to their structure modifications. HMTs displayed distinct inhibitory competencies towards TYR activity with IC₅₀ values in the range of 1.02-143.56 μM. A close correlation between their inhibition potency and both lipophilicity and molecular size was observed. The inhibitory effect of the hydroxyethyl-containing derivatives was much higher than the hydroxyethyl-free ones overall. Among them, HMT-NBO exhibited the most potent effect with IC₅₀ of 5.85 μM, which was nearly 25-fold and 3.8-fold lower than its parent HMT-NBE and the control kojic acid, respectively. The hydroxyethyl clearly benefited the improvement of the inhibitory competences and acted as a regulating group of lipophilicity of the inhibitors. The kinetic analyses showed that HMTs were reversible and mixed type inhibitors against mushroom TYR. The inhibition mechanism was studied by means of fluorescence spectroscopy, FT-IR, ESI-MS and molecular docking analysis. The results indicated that the observed inhibitory effect of HMTs was accomplished by acting on the amino acid residues rather than by chelating the centre copper ions of TYR. Each of HMTs can insert the hydrophobic pocket and interact with the residues of TYR through Van der Waals forces and hydrogen bonds, with additional electrostatic interactions for HMT-NEE and HMT-NEO further strengthening the affinity. Meanwhile, the inhibitors were observed to bind with L-DOPA or/and L-DOPAquinone forming 1:1 stoichiometric complexes, probably exerting indirect inhibition against TYR activity.

01 Jan 2018·Journal of CancerQ3 · MEDICINE

Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study

Q3 · MEDICINE

ArticleOA

Author: Hu, Xiaoyun ; Hou, Jinlin ; Liu, Li ; Li, Xiaoshuang ; He, Yajing ; Zhang, Xiaoyong ; Kong, Yanjun ; Zhou, Xiangjun ; Guo, Yabing ; Chen, Jinzhang

Background & Aims: The prognosis of hepatocellular carcinoma (HCC) remains poor and available treatment options are limited. This retrospective study evaluated the efficacy of Multiple Antigen Stimulating Cell Therapy (MASCT) as an adjuvant therapy for the treatment of HCC after curative treatment. Methods: Patients who underwent HCC curative treatments were classified into two groups: the MASCT group, in which patients received MASCT treatment after curative treatment (n = 47), and the control group, in which patients did not receive any treatment after curative treatment (n = 99). Patients who received ≥ 5 courses of MASCT treatment before recurrence or death (n = 26) were further stratified into a subgroup (multiple-course MASCT group) for analysis. The primary endpoint was overall survival (OS). The secondary endpoints were disease-free survival (DFS) and safety. Results: Kaplan-Meier analysis showed no statistically significant difference in OS between the MASCT group and the control group (P = 0.132), nor in DFS (P = 0.310) (median: 36.17 vs. 24.27 months). However, when comparing the multiple-course MASCT treated group to the control group, Kaplan-Meier analysis showed a significant difference in OS (P = 0.011), but not in DFS (P = 0.104) (median: 47.10 vs. 24.27 months). The overall incidences of treatment-related adverse events in the MASCT group and control group were 14.89% (7/47) and 19.19% (19/99), respectively. No MASCT treatment-related serious adverse events were reported. Conclusions: Although the MASCT group was not associated with significantly longer OS or DFS, the multiple-course MASCT group showed significantly improved overall survival after curative treatment, and the treatment procedures were well-tolerated. Multiple-course MASCT may therefore provide another choice for patients with HCC after curative treatment.

100 Deals associated with Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Desmoplastic Small Round Cell Tumor	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Feb 2024
Endometrial Stromal Sarcoma	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Feb 2024
Hemangiosarcoma	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Feb 2024
Malignant Fibrous Histiocytoma	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Feb 2024
Soft Tissue Sarcoma	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	10 Jan 2024
Advanced Urothelial Carcinoma	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	09 Jan 2023
metastatic non-small cell lung cancer	Phase 2	CN	The First People's Hospital of Lianyungang	01 Aug 2017
metastatic non-small cell lung cancer	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Aug 2017
Advanced Malignant Solid Neoplasm	Phase 2	CN	HRYZ (Shanghai) Biotech Co., Ltd.	01 Jul 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03034304 (MASCT-I-1001, ASCO2023) Manual	Phase 1	Metastatic urothelial carcinoma	39	platinum based-chemotherapy+MASCT-I+camrelizumab	(cgyxkdsrqj) = yzcoxvkqxt elcxaaxtfp (lhvlmniffs ) View more	Positive	26 May 2023
NCT02844881 (Pubmed \| Cancer Immunol Immunother) Manual	Phase 1/2	Solid tumor	70	MASCT	(tuvlausdzy) = lroetmrlww gviznpbjlb (vucnnhaimh ) View more	Positive	01 Sep 2019
NCT02844881 (Pubmed \| Cancer Immunol Immunother) Manual	Phase 1/2	Solid tumor	70	apatinib+MASCT	(tuvlausdzy) = zneklblofh gviznpbjlb (vucnnhaimh ) View more	Positive	01 Sep 2019